07:08 EST Autolus Therapeutics (AUTL) sees FY26 AUCATZYL revenue $120M-$135M
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics to evaluate automated manufacturing of AUCATZYL
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Needham ups Autolus target, names top pick for 2026
- Autolus Therapeutics presents data from CATULUS Phase 1 trial of obe-cel
- Autolus Therapeutics Appoints Ryan Richardson to Board